Sri Lanka Support for
Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sri Lanka

2. **Grant Number:** 1518-LKA-25c-X / 1518-LKA-25b-X / 15-LKA-08h-Y

3. **Date of Decision Letter:** 7 July 2015 (this Decision Letter replaces the previous Decision Letter for IPV dated 22 December 2014)

4. **Date of the Partnership Framework Agreement:** 3rd April, 2014

5. **Programme Title:** NVS, IPV Routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine**: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration:** 2015 - 2018

9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):**

   Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Total$³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$1,341,090</td>
<td>US$187,500</td>
<td>US$696,500</td>
<td>US$2,225,090</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** US$297,000 was approved as per Decision Letter dated 22 December 2014 and disbursed to Sri Lanka on 25 July 2014.

---

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the programme.
3 This is the total amount endorsed by Gavi for 2015 to 2017. The total amount has been revised and reduced from the previous endorsed amount based on changes to target populations, indicative wastage rates and introduction dates (where applicable). These reductions have been applied from 2016.
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): 4

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>651,300</td>
<td>93,000</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>601,200</td>
<td>19,700</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>6,625</td>
<td>225</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$1,341,090</td>
<td>US$187,500</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

13. Self-procurement: Not Applicable

14. Co-financing obligations: Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, Sri Lanka is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with Gavi Secretariat</td>
</tr>
</tbody>
</table>

17. Financial Clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

18. Other conditions: Not applicable.

If Sri Lanka envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Sri Lanka.

Signed by,
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
7 July 2015

4 This is the amount that Gavi has approved.